长期血糖控制与MASLD肝硬度进展及肝脏相关事件风险
基于VCTE-Prognosis队列7543例MASLD患者,中位随访4.1年发现,2型糖尿病与肝硬度进展(HR 1.501)和肝脏相关事件(HR 2.030)风险升高独立相关;在2型糖尿病患者中,血糖控制不佳(TWA HbA1c≥7%)与肝硬度进展风险更高相关(HR 1.524),但与肝硬度逆转或肝脏相关事件无关。
要点
- MASLD合并2型糖尿病者肝硬度进展和肝脏相关事件风险更高。
- 2型糖尿病患者血糖控制不佳与肝硬度进展风险增加相关。
- 血糖控制与肝硬度逆转或肝脏相关事件无显著关联。
核心结论
- 2型糖尿病与MASLD患者肝硬度进展和肝脏相关事件风险升高独立相关。
- 良好血糖控制与较慢的肝硬度进展相关,但与肝硬度逆转或肝脏相关事件无关。
研究设计与样本
- 基于VCTE-Prognosis队列的回顾性分析,纳入7543例接受连续VCTE和HbA1c检测的MASLD患者。
- 长期血糖控制采用时间加权平均HbA1c评估,患者分为非2型糖尿病、控制良好2型糖尿病(TWA HbA1c<7%)和控制不佳2型糖尿病(TWA HbA1c≥7%)。
- 中位随访4.1年,采用Kaplan-Meier分析和Cox比例风险模型评估肝硬度进展、逆转和肝脏相关事件。
主要发现
- 7543例MASLD患者中,4090例有2型糖尿病(2045例控制良好,2045例控制不佳),3453例无2型糖尿病。
关键数值与推荐
- 血糖控制良好定义为TWA HbA1c<7%,控制不佳定义为TWA HbA1c≥7%。
临床怎么用
- 对MASLD合并2型糖尿病患者应重视血糖长期控制以延缓肝硬度进展。
- 血糖控制良好可能减缓肝硬度进展,但未显示降低肝脏相关事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The long-term impact of type 2 diabetes (T2D) status and long-term glycemic control on disease progression and clinical outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. The study sought to assess the association of diabetes status and long-term glycemic control with liver stiffness progression or regression, and liver-related events (LREs) in MASLD. METHODS: We analyzed patients with MASLD from the VCTE-Prognosis cohort who underwent serial vibration-controlled transient elastography (VCTE) assessments and hemoglobin A1c (HbA1c) measurements. Long-term glycemic control was evaluated using the time-weighted average (TWA) HbA1c, which reflects both the magnitude and duration of glycemia. Patients were categorized as non-T2D, well-controlled T2D (TWA HbA1c<7%), or poorly controlled T2D (TWA HbA1c ≥7%). Liver stiffness progression, regression, and LREs were examined using Kaplan-Meier analyses and Cox proportional hazards models. RESULTS: Of 7543 patients with MASLD, 4090 had T2D (2045 well controlled, 2045 poorly controlled) and 3453 did not have T2D. Over a median follow-up of 4.1 years, patients with T2D had a higher risk of liver stiffness progression (hazard ratio [HR], 1.501, 95% confidence interval [CI]. 1.148-1.962; P = .003) and LREs (HR, 2.030; 95% CI, 1.241-3.320; P = .005), but not liver stiffness regression, compared with non-T2D patients. Among patients with T2D, poor glycemic control was associated with a higher risk of liver stiffness progression compared with good glycemic control (HR, 1.524; 95% CI, 1.182-1.965; P = .001). No differences were observed for liver stiffness regression (P = .957) or LREs (P = .625) with glycemic control. Findings were consistent across sensitivity analyses. CONCLUSIONS: T2D was independently associated with a higher risk of liver stiffness progression and LREs in MASLD. Good glycemic control was associated with slower liver stiffness progression, but not regression or LREs.
引用
- Zhou XD, Chen QF, Kim SU, et al. Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD. Clin Gastroenterol Hepatol. 2025. PMID: 41076043. doi:10.1016/j.cgh.2025.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。